Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Payables (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Payables for 12 consecutive years, with $979038.0 as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 582.2% to $979038.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $979038.0, a 582.2% increase, with the full-year FY2025 number at $1.0 million, up 96.01% from a year prior.
  • Payables was $979038.0 for Q4 2025 at Regen BioPharma, down from $1.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.3 million in Q3 2021 to a low of $29416.0 in Q2 2024.
  • A 5-year average of $369712.0 and a median of $109677.0 in 2021 define the central range for Payables.
  • Biggest YoY gain for Payables was 3708.22% in 2022; the steepest drop was 97.65% in 2022.
  • Regen BioPharma's Payables stood at $33288.0 in 2021, then soared by 3708.22% to $1.3 million in 2022, then plummeted by 96.44% to $45183.0 in 2023, then surged by 217.62% to $143512.0 in 2024, then surged by 582.2% to $979038.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Payables are $979038.0 (Q4 2025), $1.0 million (Q3 2025), and $130477.0 (Q2 2025).